Navigation Links
Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
Date:9/3/2013

.30 miles west of Akron, and other related healthcare facilities and services. Community Health Systems stated that the parties will complete the due diligence process and work toward finalizing the terms of a definitive agreement. Wayne T. Smith, Chairman, President and CEO of CHS said, "The strategic alliance formed between Cleveland Clinic and Community Health Systems earlier this year is gaining momentum as we work together to advance high-quality, cost-effective healthcare services within our own organizations," The Full Research Report on Community Health Systems Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/7587_CYH]

Neurocrine Biosciences, Inc. Research Report  

On August 29, 2013, Neurocrine Biosciences Inc. (Neurocrine Biosciences) announced that in accordance to the Company's collaboration with AbbVie for elagolix in 2010, the latter has initiated the second Phase III pivotal trial to evaluate elagolix for the treatment of endometriosis. Neurocrine Biosciences informed that the second Phase III trial is a 24-week, multinational, randomized double-blind placebo-controlled study designed to evaluate the safety and efficacy of elagolix in 788 women, age 18-49, with moderate-to-severe endometriosis-associated pain. The Company expects to provide top-line data from the second Phase III trial in Q3 2014 and complete in 2015. The Full Research Report on Neurocrine Biosciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/8228_NBIX]

Alnylam Pharmaceuticals Inc. Research Report<
'/>"/>

SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Arena Pharmaceuticals Completes Phase 1b Clinical Trial Evaluating APD811 for Pulmonary Arterial Hypertension
2. Magellan Diagnostics Receives FDA Clearance for LeadCare Ultra Bench-top Clinical Lead Analyzer
3. Cellular Biomedicine Group Announces Completion of Patient Enrollment for Phase I Clinical Trial for Liver Cancer
4. Selexys Pharmaceuticals Initiates SUSTAIN Phase 2 Clinical Trial in Sickle Cell Patients with Pain Crises
5. Final Patient Completes Prosonix Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
6. Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial
7. Start-up Seeks Crowd Funding to Complete Clinical Studies Supporting Breakthrough Blood Test for Earlier Detection of Melanoma
8. MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development
9. Neuralstem Reports Second Quarter Financial Results And Provides Business And Clinical Update
10. Sanarias Malaria Vaccine Yields Unprecedented Protection In Phase 1 Clinical Trial
11. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... 2012  JARVIK HEART, Inc., a privately-held company that develops ... of its Pivotal Trial for evaluation of the Jarvik ... device for DT means that it will provide long-term, ... are not candidates for heart transplant. The approval permits ...
... Feb. 27, 2012 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited ... and marketer of medical devices worldwide, announced today its ... full year ended December 31, 2011. ... Fourth quarter net revenue increased 25.2% year-over-year ...
Cached Medicine Technology:JARVIK HEART Announces FDA Conditional Approval of Trial Using the Jarvik 2000® Heart for Destination Therapy 2JARVIK HEART Announces FDA Conditional Approval of Trial Using the Jarvik 2000® Heart for Destination Therapy 3Mindray Announces 2011 Fourth Quarter and Full Year Results 2Mindray Announces 2011 Fourth Quarter and Full Year Results 3Mindray Announces 2011 Fourth Quarter and Full Year Results 4Mindray Announces 2011 Fourth Quarter and Full Year Results 5Mindray Announces 2011 Fourth Quarter and Full Year Results 6Mindray Announces 2011 Fourth Quarter and Full Year Results 7Mindray Announces 2011 Fourth Quarter and Full Year Results 8Mindray Announces 2011 Fourth Quarter and Full Year Results 9Mindray Announces 2011 Fourth Quarter and Full Year Results 10Mindray Announces 2011 Fourth Quarter and Full Year Results 11Mindray Announces 2011 Fourth Quarter and Full Year Results 12Mindray Announces 2011 Fourth Quarter and Full Year Results 13Mindray Announces 2011 Fourth Quarter and Full Year Results 14Mindray Announces 2011 Fourth Quarter and Full Year Results 15Mindray Announces 2011 Fourth Quarter and Full Year Results 16Mindray Announces 2011 Fourth Quarter and Full Year Results 17
(Date:4/24/2014)... often coexist with the negative and stressful outcomes for ... diagnosed with a life-limiting illness, says a recent study ... , While the challenges are numerous and life-changing and ... participated in the Waterloo-led research reported positive outcomes as ... appear in the most recent issue of the ...
(Date:4/24/2014)... in the new Institute for Biomedical Sciences at ... million federal grant to develop novel therapeutics against ... from the Eunice Kennedy Shriver National Institute Of ... Institutes of Health will support Plemper,s drug development ... least one distinct alternative compound. , Infections by ...
(Date:4/24/2014)... Ill. It is better to give than to receive ... giving, a new study suggests. , The study found that ... as giving their money to family members, are less likely ... from taking risks or keeping the money for themselves. , ... the National Academy of Sciences . , The study focused ...
(Date:4/24/2014)... influenza pH1N1 virus caused the first flu pandemic in ... 2009 and killed more than 50 people in the ... during flu epidemics (winter/spring seasons). , Infections with ... illnesses. World Health Organization has recommended Tamiflu for treatment ... of this drug is that it targets viral proteins ...
(Date:4/23/2014)... say clinical trials for a new experimental drug ... promising. Patients treated with CPX-351, a combination of ... better responses than patients treated with the standard ... leukemia is an aggressive blood cancer with very ... patients," explained Jeffrey Lancet, M.D., senior member of ...
Breaking Medicine News(10 mins):Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2
... LANSING, Mich. To tackle the growing number of psychiatric cases ... team of Michigan State University doctors from the colleges of ... from across the state via video conference. , On ... see up to 10 patients each from as far away ...
... study says , , MONDAY, Oct. 27 (HealthDay News) -- ... coronary conditions, might reduce the effect of the clot-preventing ... blockers appear to inactivate an enzyme essential for the ... published online Oct. 28 in the Journal of ...
... Treatment, ST. LOUIS, Oct. 27 Leading ... deliver radioactive seed therapy,in the prostate. The innovative ... the prostate during procedures. With the gland stabilized,physicians ... to map,and confirm placement of radiation., Unveiled ...
... Study found desires remained essentially unchanged over 3-year period ... declines in either mental or physical health, most senior ... want their end-of-life care to be when the time ... that despite observing an overall stability in patient perspective, ...
... Oct. 27 SpectraCell Laboratories, Inc.,announced that ... facilities. Recently,SpectraCell occupied a 20,000 sq. ft. ... 2005. The planned expansion added a second ... campus. The new $3.5 million facility houses,SpectraCell,s ...
... an initial,step in the creation of a wellness ... it has acquired HealthMedia, Inc., a,privately held company ... change interventions. Terms of the transaction were not,disclosed., ... to,effectively emulate a health coach via the web. ...
Cached Medicine News:Health News:MSU doctors bring much-needed psychiatric care to rural areas via technology 2Health News:Common Heart Drugs May Hamper Blood Thinner 2Health News:Common Heart Drugs May Hamper Blood Thinner 3Health News:Doctors Test Advanced Tool for Treating Prostate Cancer 2Health News:Seniors Tend to Stick With End-of-Life Care Preferences 2Health News:Seniors Tend to Stick With End-of-Life Care Preferences 3Health News:SpectraCell Laboratories Expands Operations in New Facility 2Health News:Johnson & Johnson Establishes Wellness & Prevention Platform with Acquisition of HealthMedia, Inc. 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: